Connecting via Winsock to STN

Claims 23 ≟ 49

Welcome to STN International! Enter x:x

LOGINID:SSPTAJMN1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAplus patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS	23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	30	Feb 26	MEDLINE reloaded with enhancements
NEWS	31	Feb 26	EMBASE enhanced with Clinical Trial Number field
NEWS	32	Feb 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	33	Feb 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	34	Feb 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS EXPRESS   NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT

MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS   STN Operating Hours Plus Help Desk Availability
NEWS LOGIN   Welcome Banner and News Items
NEWS IPC8   For general information regarding STN implementation of IPC 8
NEWS X25   X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

   All use of STN is subject to the provisions of the STN Customer
   agreement. Please note that this agreement limits use to scientific
   research. Use for software development or design or implementation
   of commercial gateways or other similar uses is prohibited and may
   result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:28:50 ON 06 MAR 2007

=> fil reg
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                               ENTRY   SESSION
FULL ESTIMATED COST   0.21   0.21

FILE 'REGISTRY' ENTERED AT 12:29:01 ON 06 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAR 2007   HIGHEST RN 924962-30-1
DICTIONARY FILE UPDATES: 5 MAR 2007   HIGHEST RN 924962-30-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

   Please note that search-term pricing does apply when
   conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\5.str

chain nodes :
10 11 12 13 14 15 26
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-11 9-10 11-12 12-13 13-14 14-15
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 7-8 8-9 11-12 12-13 14-15
exact bonds :
7-11 9-10 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Any 26:CLASS 27:Atom
Generic attributes :
15:
Saturation   : Unsaturated

Element Count :
Node 15: Limited
    C,C6-14

L1   STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS

L1   STR

Structure attributes must be viewed using STN Express query preparation.


```
=> s l1 full
FULL SEARCH INITIATED 12:29:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   379273 TO ITERATE

100.0% PROCESSED   379273 ITERATIONS                2488 ANSWERS
SEARCH TIME: 00.00.03

L2       2488 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\claim 23a.str
```



```
chain nodes :
10  11  12  13  14  15  24
ring nodes :
1  2  3  4  5  6  7  8  9
```

chain bonds :
7-11   9-10   11-12   12-13   13-14   14-15
ring bonds :
1-2   1-6   2-3   2-7   3-4   3-9   4-5   5-6   7-8   8-9
exact/norm bonds :
2-7   3-9   7-8   8-9   11-12   12-13   14-15
exact bonds :
7-11   9-10   13-14
normalized bonds :
1-2   1-6   2-3   3-4   4-5   5-6

Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom   2:Atom   3:Atom   4:Atom   5:Atom   6:Atom   7:Atom   8:Atom   9:Atom   10:CLASS
11:CLASS   12:CLASS   13:CLASS   14:CLASS   15:Any   24:CLASS   25:Atom
Generic attributes :
15:
Saturation   : Unsaturated

Element Count :
Node 15: Limited
     C,C6-14

L3   STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3   STR

Structure attributes must be viewed using STN Express query preparation.

=> s l3 full sub=l2
FULL SUBSET SEARCH INITIATED 12:29:56 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -   1032 TO ITERATE

100.0% PROCESSED   1032 ITERATIONS   1028 ANSWERS
SEARCH TIME: 00.00.01

L4   1028 SEA SUB=L2 SSS FUL L3

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\claim 23ac.str

chain nodes :
10 11 12 13 14 15 24 26
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-11 9-10 11-12 12-13 13-14 13-26 14-15
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 7-8 8-9 11-12 12-13 13-26 14-15
exact bonds :
7-11 9-10 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Any 24:CLASS 25:Atom 26:CLASS
Generic attributes :
15:
Saturation   : Unsaturated

Element Count :
Node 15: Limited
     C,C6-14

L5   STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5   .   STR

Structure attributes must be viewed using STN Express query preparation.

=> s 15 full sub=14
FULL SUBSET SEARCH INITIATED 12:31:08 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -   1028 TO ITERATE

100.0% PROCESSED   1028 ITERATIONS   1 ANSWERS
SEARCH TIME: 00.00.01

L6   1 SEA SUB=L4 SSS FUL L5

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\claim 23ab.str

```
chain nodes :
10   11   12   13   14   15   24   26
ring nodes :
1   2   3   4   5   6   7   8   9
chain bonds :
7-11   9-10   11-12   12-13   13-14   14-15   14-26
ring bonds :
1-2   1-6   2-3   2-7   3-4   3-9   4-5   5-6   7-8   8-9
exact/norm bonds :
2-7   3-9   7-8   8-9   11-12   12-13   14-15   14-26
exact bonds :
7-11   9-10   13-14
normalized bonds :
1-2   1-6   2-3   3-4   4-5   5-6


Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom   2:Atom   3:Atom   4:Atom   5:Atom   6:Atom   7:Atom   8:Atom   9:Atom   10:CLASS
11:CLASS   12:CLASS   13:CLASS   14:CLASS   15:Any   24:CLASS   25:Atom   26:CLASS
Generic attributes :
15:
Saturation                 : Unsaturated

Element Count :
Node 15: Limited
    C,C6-14
```

L7   STRUCTURE UPLOADED

```
=> d
L7 HAS NO ANSWERS
L7                STR
```


Structure attributes must be viewed using STN Express query preparation.

```
=> s l7 full sub=l4
FULL SUBSET SEARCH INITIATED 12:31:40 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -     1028 TO ITERATE

100.0% PROCESSED     1028 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.01

L8           0 SEA SUB=L4 SSS FUL L7

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\claim 49.str
```

chain nodes :
10 11 12 13 14 15 26 28
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
6-28 7-11 9-10 11-12 12-13 13-14 14-15
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 6-28 7-8 8-9 11-12 12-13 14-15
exact bonds :
7-11 9-10 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Any 26:CLASS 27:Atom 28:Atom
Generic attributes :
15:
Saturation   : Unsaturated

Element Count :
Node 15: Limited
    C,C6-14

L9   STRUCTURE UPLOADED

=> d
L9 HAS NO ANSWERS

L9   STR

Structure attributes must be viewed using STN Express query preparation.

=> s 19 full sub=12
FULL SUBSET SEARCH INITIATED 12:32:28 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -   2488 TO ITERATE

100.0% PROCESSED   2488 ITERATIONS   97 ANSWERS
SEARCH TIME: 00.00.01

L10   97 SEA SUB=L2 SSS FUL L9

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\claim 49a.str

chain nodes :
10   11   12   13   14   15   26   28

ring nodes :
1 2   3   4   5   6   7   8   9
chain bonds :
6-28   7-11   9-10   11-12   12-13   13-14   14-15
ring bonds :
1-2   1-6   2-3   2-7   3-4   3-9   4-5   5-6   7-8   8-9
exact/norm bonds :
2-7   3-9   6-28   7-8   8-9   11-12   12-13   14-15
exact bonds :
7-11   9-10   13-14
normalized bonds :
1-2   1-6   2-3   3-4   4-5   5-6

Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Any 26:CLASS 27:Atom 28:Atom
Generic attributes :
15:
Saturation   : Unsaturated
28:
Saturation   : Unsaturated
Number of Carbon Atoms : less than 7

Element Count :
Node 15: Limited
    C,C6-14

L11   STRUCTURE UPLOADED

=> d
L11 HAS NO ANSWERS
L11   STR

Structure attributes must be viewed using STN Express query preparation.

=> s l11 full sub=l10
FULL SUBSET SEARCH INITIATED 12:33:50 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -   97 TO ITERATE

100.0% PROCESSED   97 ITERATIONS   89 ANSWERS
SEARCH TIME: 00.00.01

L12   89 SEA SUB=L10 SSS FUL L11

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\claim 49b.str

chain nodes :
10   11   12   13   14   15   26   28
ring nodes :

```
1  2  3  4  5  6  7  8  9
chain bonds :
6-28   7-11   9-10   11-12   12-13   13-14   14-15
ring bonds :
1-2  1-6  2-3  2-7  3-4  3-9  4-5  5-6  7-8  8-9
exact/norm bonds :
2-7  3-9  6-28  7-8  8-9  11-12  12-13  14-15
exact bonds :
7-11   9-10   13-14
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6      .
```

Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Any 26:CLASS 27:Atom 28:Atom
Generic attributes :
15:
Saturation   : Unsaturated
28:
Saturation   : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System   : Monocyclic

Element Count :
Node 15: Limited
     C,C6-14

L13   STRUCTURE UPLOADED

=> d
L13 HAS NO ANSWERS
L13   STR

A

H

Structure attributes must be viewed using STN Express query preparation.


```
=> s l13 full sub=l10
FULL SUBSET SEARCH INITIATED 12:35:04 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -       97 TO ITERATE

100.0% PROCESSED       97 ITERATIONS                        89 ANSWERS
SEARCH TIME: 00.00.01

L14           89 SEA SUB=L10 SSS FUL L13

=> fil caplus
COST IN U.S. DOLLARS                        SINCE FILE       TOTAL
                                               ENTRY        SESSION
FULL ESTIMATED COST                           420.05        420.26

FILE 'CAPLUS' ENTERED AT 12:35:12 ON 06 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE COVERS 1907 - 6 Mar 2007   VOL 146 ISS 11
FILE LAST UPDATED: 5 Mar 2007   (20070305/ED)
```

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

        (FILE 'HOME' ENTERED AT 12:28:50 ON 06 MAR 2007)

        FILE 'REGISTRY' ENTERED AT 12:29:01 ON 06 MAR 2007
L1   STRUCTURE UPLOADED
L2   2488 S L1 FULL
L3   STRUCTURE UPLOADED
L4   1028 S L3 FULL   SUB=L2
L5   STRUCTURE UPLOADED
L6   1 S L5 FULL   SUB=L4
L7   STRUCTURE UPLOADED
L8   0 S L7 FULL   SUB=L4
L9   STRUCTURE UPLOADED
L10   97 S L9 FULL   SUB=L2
L11   STRUCTURE UPLOADED
L12   89 S L11 FULL SUB=L10
L13   STRUCTURE UPLOADED
L14   89 S L13 FULL SUB=L10

        FILE 'CAPLUS' ENTERED AT 12:35:12 ON 06 MAR 2007

=> s 16
L15   1 L6   — not prior art

=> s 110
L16   1 L10 — its own instant app

=> s 115 or 116
L17   2 L15 OR L16

=> d ibib abs hitstr l15

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:356982 CAPLUS
DOCUMENT NUMBER: 144:412514
TITLE: Preparation of indazoles, benzisoxazoles, and
                        benzisothiazoles as estrogenic agents
INVENTOR(S):   Rondot, Benoit; Bonnet, Paule; Duc, Igor; Lafay,
Jean;
                        Clerc, Thierry; Duranti, Eric; Puccio, Francois;
Blot,
                        Christian; Shields, Jacqueline; Maillos, Philippe
PATENT ASSIGNEE(S):   Laboratoire Theramex, Monaco
SOURCE: Eur. Pat. Appl., 44 pp.
                        CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

     PATENT NO.   KIND   DATE   APPLICATION NO.   DATE
     -----------   ----   --------   --------------------   --------
     EP 1647549   A1   20060419   EP 2004-292439   20041014
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
HR
     WO 2006040351   A1   20060420   WO 2005-EP55262   20051014
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
            NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
            SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
            YU, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:   EP 2004-292439   A 20041014

OTHER SOURCE(S):   MARPAT 144:412514
GI

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN   (Continued)

AB   The title indazoles, benzisoxazoles, and benzisothiazoles with general
     formula of I [wherein R1 = H, CF3, (un)substituted -N=CH2, alkyl, Ph,
     etc.; R2 and R3 = independently H, OH, halo, NO2, CN, etc.; X = O, S, SO,
     SO2, or (un)substituted NH; Y = a bond, O, S, SO, SO2, CO, etc.; A =
     (un)substituted cycloalkyl, cycloalkenyl, Ph, or naphthyl; with
provisos],
     or pharmaceutically acceptable salts or stereoisomers thereof were
prepared
     as modulators of estrogen receptors. For example, (4-benzyloxy-2-
     fluorophenyl)methanone (preparation given) was reacted with hydrazine
hydrate,
     followed by hydrogenolysis in ethanol in the presence of Pd/C and PtO2 to
     give II. II showed biol. activity with IC50 = 41.8 ± 7.1 nM against
     human estrogen β receptor. The compds. are useful for the prevention
     or treatment of estrogenic disorders, such as schizophrenia,
     neurodegenerative diseases, reproductive disorders, etc. (no data).
IT   883717-53-1P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (drug candidate; preparation of indazoles, benzisoxazoles, and
        benzisothiazoles as estrogenic agents)
RN   883717-53-1 CAPLUS
CN   1H-Indazole-3-acetonitrile, 6-methoxy-α-[(4-methoxyphenyl)methylene]-
     (9CI)   (CA INDEX NAME)

REFERENCE COUNT: 11   THERE ARE 11 CITED REFERENCES AVAILABLE FOR
THIS
                                  RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:972059 CAPLUS
DOCUMENT NUMBER: 140:27819
TITLE: Preparation of pyrazole derivatives as JNK inhibitors
INVENTOR(S): Ohi, Norihito; Sato, Nobuaki; Soejima, Motohiro;
Doko,

Takashi; Terauchi, Taro; Naoe, Yoshimitsu; Motoki,
Takafumi
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 561 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101968	A1	20031211	WO 2003-JP6777	20030529

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2482838	A1	20031211	CA 2003-2482838	20030529
AU 2003241925	A1	20031219	AU 2003-241925	20030529
EP 1510516	A2	20050302	EP 2003-733170	20030529

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1656079	A	20050817	CN 2003-812475	20030529
US 2005208582	A1	20050922	US 2003-447948	20030530
US 2005261339	A1	20051124	US 2005-509795	20050225
			JP 2002-158467	A 20020531

PRIORITY APPLN. INFO.:

| | | | JP 2003-153 | A 20030106 |
| | | | WO 2003-JP677 | W 20030529 |

OTHER SOURCE(S): MARPAT 140:27819
GI

I

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB The title compds. I [R1 represents (CO)h(NRa)j(CRb:CRc)kAr (wherein Ra,
Rb, and Rc each independently represents hydrogen, halogeno, hydroxy,
optionally substituted C1-6 alkyl, etc.); Ar = (un)substituted aromatic
heterocyclic ring, etc.; h, j, k = 0 or 1; Cy is a 5- or 6-membered
aromatic
heterocycle; and V represents L-X-Y (wherein L is a single bond,
optionally substituted C1-6 alkylene, etc.; X is a single bond, O, CO,
etc.; and Y is hydrogen, halogeno, nitro, etc.); n = 0 - 4] are prepared
Compds. of this invention in vitro showed IC50 values of 63 nM to 578 nM
against JNK-3.
IT 633325-20-9P 633325-21-0P 633325-22-1P
633325-23-2P 633325-25-4P 633325-26-5P
633325-27-6P 633325-28-7P 633325-31-2P
633325-32-3P 633325-33-4P 633325-34-5P
633326-02-0P 633326-03-1P 633326-04-2P
633326-05-3P 633326-06-4P 633326-07-5P
633326-08-6P 633326-09-7P 633326-10-0P
633326-11-1P 633326-12-2P 633326-13-3P
633326-14-4P 633326-15-5P 633326-16-6P
633326-17-7P 633326-18-8P 633326-19-9P
633326-20-2P 633326-21-3P 633326-22-4P
633326-23-5P 633326-24-6P 633326-25-7P
633326-26-8P 633326-27-9P 633326-28-0P
633326-29-1P 633326-30-4P 633326-31-5P
633326-32-6P 633326-33-7P 633326-34-8P
633326-35-9P 633326-36-0P 633326-37-1P
633326-39-3P 633326-40-6P 633326-41-7P
633326-42-8P 633326-43-9P 633326-44-0P
633326-45-1P 633326-46-2P 633326-47-3P
633326-48-4P 633326-49-5P 633326-50-8P
633326-51-9P 633326-52-0P 633326-53-1P
633326-54-2P 633326-55-3P 633326-56-4P
633326-57-5P 633326-58-6P 633326-59-7P
633333-19-4P 633333-20-7P 633333-21-8P
633333-22-9P 633333-23-0P 633333-24-1P
633333-25-2P 633333-26-3P 633333-27-4P
633333-28-5P 633333-29-6P 633333-30-9P
633333-31-0P 633333-32-1P 633333-33-2P
633333-34-3P 633333-35-4P 633333-36-5P
633333-37-6P 633333-38-7P 633333-39-8P
633333-40-1P 633333-41-2P 633334-90-4P
633334-91-5P 633334-92-6P 633334-93-7P
633334-94-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of pyrazole derivs. as JNK inhibitors)
RN 633325-20-9 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(3-fluorophenyl)ethenyl]-5-(5-methyl-1H-
1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 633325-21-0 CAPLUS
CN 1H-1,2,4-Triazole-3-methanol, 5-[7-fluoro-3-[(1E)-2-(3-
fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633325-22-1 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-(7-fluoro-3-[(1E)-2-(3-
fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,N-dimethyl- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 633325-23-2 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(3-
fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633325-25-4 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(3-fluorophenyl)ethenyl]-5-(5-methyl-1H-
1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633325-26-5 CAPLUS
CN   1H-1,2,4-Triazole-3-methanol, 5-[6-fluoro-3-[(1E)-2-(3-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633325-27-6 CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(3-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,N-dimethyl- (9CI)   (CA INDEX
     NAME)

Double bond geometry as shown.

RN   633325-28-7 CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(3-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633325-31-2 CAPLUS
CN   1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(5-methyl-1H-
     1,2,4-triazol-3-yl)- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633325-32-3 CAPLUS
CN   1H-1,2,4-Triazole-3-methanol, 5-[7-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633325-33-4 CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-
   fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633325-34-5 CAPLUS
CN   1H-Indazole, 3-[(1E)-2-(3-fluorophenyl)ethenyl]-4-methoxy-5-(5-methyl-1H-
     1,2,4-triazol-3-yl)- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-02-0 CAPLUS
CN   1H-1,2,4-Triazole-3-methanol, 5-[6-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-α-methyl- (9CI)   (CA INDEX
     NAME)

Double bond geometry as shown.

RN   633326-03-1 CAPLUS
CN   1H-1,2,4-Triazole-3-propanol, 5-[6-fluoro-3-[(1E)-2-(4-
      fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-04-2 CAPLUS
CN   1H-1,2,4-Triazole-3-methanol, 5-[7-fluoro-3-[(1E)-2-(4-
      fluorophenyl)ethenyl]-1H-indazol-5-yl]-α-methyl- (9CI)   (CA INDEX
      NAME)

Double bond geometry as shown.

RN   633326-05-3 CAPLUS
CN   1H-1,2,4-Triazole-3-propanol, 5-[7-fluoro-3-[(1E)-2-(4-
      fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-06-4 CAPLUS
CN   1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1H-1,2,4-
      triazol-3-yl)- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-07-5 CAPLUS
CN   1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1H-1,2,4-
   triazol-3-yl)- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-08-6 CAPLUS
CN   1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(5-methyl-1H-
      1,2,4-triazol-3-yl)- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-09-7 CAPLUS
CN   1H-1,2,4-Triazole-3-methanol, 5-[6-fluoro-3-[(1E)-2-(4-
      fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-10-0 CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-
   fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

```
RN   633326-11-1  CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,N-dimethyl- (9CI)  (CA INDEX
     NAME)
```

Double bond geometry as shown.


```
RN   633326-12-2  CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI)  (CA INDEX NAME)
```

Double bond geometry as shown.

```
RN   633326-13-3  CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-α-(1-methylethyl)-,
     (αS)- (9CI)  (CA INDEX NAME)
```

Absolute stereochemistry.
Double bond geometry as shown.


```
RN   633326-14-4  CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,N-dimethyl- (9CI)  (CA INDEX
     NAME)
```

Double bond geometry as shown.

```
RN   633326-15-5  CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI)  (CA INDEX NAME)
```

Double bond geometry as shown.


```
RN   633326-16-6  CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-α-(1-methylethyl)-,
     (αS)- (9CI)  (CA INDEX NAME)
```

Absolute stereochemistry.
Double bond geometry as shown.

```
RN   633326-17-7  CAPLUS
CN   1H-1,2,4-Triazole-3-methanol, 5-[7-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-α,α-dimethyl- (9CI)
     (CA INDEX NAME)
```

Double bond geometry as shown.


```
RN   633326-18-8  CAPLUS
CN   1H-1,2,4-Triazole-3-methanol, 5-[6-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-α,α-dimethyl- (9CI)
     (CA INDEX NAME)
```

Double bond geometry as shown.

RN   633326-19-9 CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-α,α-dimethyl- (9CI)
     (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-20-2 CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-α,α-dimethyl- (9CI)
   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-21-3 CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl-α-(1-methylethyl)-,
     (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN   633326-22-4 CAPLUS
CN   Cyclopropanamine, 1-[5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-
     indazol-5-yl]-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-23-5 CAPLUS
CN   Cyclopropanamine, 1-[5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-
     indazol-5-yl]-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-24-6 CAPLUS
CN   1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(2-
     thienylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-25-7 CAPLUS
CN   1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-
     (phenylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-26-8 CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-α-(phenylmethyl)-,
   (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN   633326-27-9 CAPLUS
CN   1H-1,2,4-Triazole-3-ethanamine, 5-[6-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,N-dimethyl- (9CI)   (CA INDEX
     NAME)

Double bond geometry as shown.

RN   633326-28-0 CAPLUS
CN   1H-1,2,4-Triazole-3-ethanamine, 5-[7-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,N-dimethyl- (9CI)   (CA INDEX
     NAME)

Double bond geometry as shown.

RN   633326-29-1 CAPLUS
CN   1H-Indazole,
     5-[5-(3-azetidinyl)-1H-1,2,4-triazol-3-yl]-6-fluoro-3-[(1E)-2-
     (4-fluorophenyl)ethenyl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-30-4 CAPLUS
CN   1H-Indazole,
     5-[5-(3-azetidinyl)-1H-1,2,4-triazol-3-yl]-7-fluoro-3-[(1E)-2-
     (4-fluorophenyl)ethenyl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-31-5 CAPLUS
CN   1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1-methyl-1H-
   1,2,4-triazol-3-yl)- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-32-6 CAPLUS
CN   1H-Indazole,
     5-(1,5-dimethyl-1H-1,2,4-triazol-3-yl)-6-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-33-7 CAPLUS
CN   1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1-methyl-1H-
     1,2,4-triazol-3-yl)- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-34-8 CAPLUS
CN   1H-1,2,4-Triazole-3-acetamide, 5-[6-fluoro-3-[(1E)-2-(4-
   fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-35-9 CAPLUS
CN   1H-1,2,4-Triazole-3-acetamide, 5-[7-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-36-0 CAPLUS
CN   1,3,4-Oxadiazole-2-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,α,α-trimethyl- (9CI)
     (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-37-1 CAPLUS
CN   1,3,4-Oxadiazole-2-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-α-(1-methylethyl)-,
     (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN   633326-39-3 CAPLUS
CN   1H-Indazole,
     6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(2-pyrimidinyl)-
     (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-40-6 CAPLUS
CN   1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(4-methyl-2-
     pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-41-7 CAPLUS
CN   1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(5-methyl-2-
     pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-42-8 CAPLUS
CN   1H-Indazole,
     7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1H-imidazol-2-
     yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-43-9 CAPLUS
CN   1H-Imidazole-4-methanol,
     2-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-
     indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-44-0 CAPLUS
CN   1H-Indazole,
     6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1H-imidazol-2-
     yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633326-45-1 CAPLUS
CN 1H-Imidazole-4-methanol,
2-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-
    indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633326-46-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-
    indazol-5-yl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633326-47-3 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-
    1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633326-48-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 4-amino-5-[7-fluoro-3-[(1E)-2-(4-
    fluorophenyl)ethenyl]-1H-indazol-5-yl]-2,4-dihydro- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.

RN 633326-49-5 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-
    1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633326-50-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-
    indazol-5-yl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633326-51-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 4-amino-5-[6-fluoro-3-[(1E)-2-(4-
    fluorophenyl)ethenyl]-1H-indazol-5-yl]-2,4-dihydro- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.

RN 633326-52-0 CAPLUS
CN 1H-Indazole, 5-(1H-benzimidazol-2-yl)-6-fluoro-3-[(1E)-2-(4-
   fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-53-1 CAPLUS
CN   1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(4-methyl-1H-
      benzimidazol-2-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-54-2 CAPLUS
CN   1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(5-methyl-1H-
      benzimidazol-2-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-55-3 CAPLUS
CN   1H-Indazole, 5-(5-chloro-1H-benzimidazol-2-yl)-6-fluoro-3-[(1E)-2-(4-
      fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-56-4 CAPLUS
CN   1H-Indazole, 6-fluoro-5-(5-fluoro-1H-benzimidazol-2-yl)-3-[(1E)-2-(4-
      fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-57-5 CAPLUS
CN   1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(5-nitro-1H-
      benzimidazol-2-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-58-6 CAPLUS
CN   1H-Indazole, 5-(5,6-dichloro-1H-benzimidazol-2-yl)-6-fluoro-3-[(1E)-2-(4-
      fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633326-59-7 CAPLUS
CN   1H-Indazole,
      5-(5-chloro-6-fluoro-1H-benzimidazol-2-yl)-6-fluoro-3-[(1E)-2-
      (4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633333-19-4 CAPLUS
CN   1,3,4-Oxadiazole-2-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-
      fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633333-20-7 CAPLUS
CN   Cyclopropanamine, 1-[5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-
   indazol-5-yl]-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633333-21-8 CAPLUS
CN   1,3,4-Oxadiazole-2-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-
      fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633333-22-9 CAPLUS
CN   Cyclopropanamine, 1-[5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-
      indazol-5-yl]-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN   633333-23-0 CAPLUS
CN   1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(4-
   piperidinyl)-1H-1,2,4-triazol-3-yl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633333-25-2 CAPLUS
CN   Cyclopentanamine, 1-[5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-
   indazol-5-yl]-1H-1,2,4-triazol-3-yl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633333-24-1 CAPLUS
CN   1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(3-
     pyridinylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633333-26-3 CAPLUS
CN   1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(4-
     piperidinylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633333-27-4 CAPLUS
CN   1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(1-
     piperidinylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN   633333-29-6 CAPLUS
CN   1H-1,2,4-Triazole-5-methanamine, 3-[7-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,1-dimethyl- (9CI)   (CA INDEX
     NAME)

Double bond geometry as shown.

RN   633333-28-5 CAPLUS
CN   1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-
     fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl-α-(1-methylethyl)-,
     (αS)- (9CI)   (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN   633333-30-9 CAPLUS
CN   1H-Indazole, 5-(4,5-dihydro-1H-imidazol-2-yl)-6-fluoro-3-[(1E)-2-(4-
   fluorophenyl)ethenyl]- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.

RN 633333-31-0 CAPLUS
CN 1H-Indazole,
5-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)-6-fluoro-3-[(1E)-2-
(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633333-32-1 CAPLUS
CN 1H-Indazole,
5-(4,5-dihydro-4-methyl-1H-imidazol-2-yl)-6-fluoro-3-[(1E)-2-
(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633333-33-2 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1,4,5,6-
tetrahydro-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633333-34-3 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1,4,5,6-
tetrahydro-1-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633333-35-4 CAPLUS
CN 5-Pyrimidinol,
2-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-

yl]-1,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633333-36-5 CAPLUS
CN 1H-Indazole, 5-(4,5-dihydro-1H-imidazol-2-yl)-7-fluoro-3-[(1E)-2-(4-
fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633333-37-6 CAPLUS
CN 1H-Indazole,
5-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)-7-fluoro-3-[(1E)-2-
(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633333-38-7 CAPLUS
CN 1H-Indazole,
5-(4,5-dihydro-4-methyl-1H-imidazol-2-yl)-7-fluoro-3-[(1E)-2-
(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633333-39-8 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1,4,5,6-
tetrahydro-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633333-40-1 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633333-41-2 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1,4,5,6-tetrahydro-5-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633334-90-4 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633334-91-5 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(1-piperidinylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633334-92-6 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(3-pyridinylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633334-93-7 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(4-piperidinyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 633334-94-8 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(4-piperidinylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR
THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT